The European Commission has approved single-agent nivolumab (Opdivo) for use in the adjuvant treatment of adult and adolescent patients aged 12 years or older who have stage IIB or IIC melanoma and who have undergone complete resection.
Publications
FDA Approves HEPZATO KIT for Adults Metastatic With Uveal Melanoma
The first liver-directed therapy for the treatment of adult with metastatic uveal melanoma is now FDA approved.
MRV Newsletter – October 2023
>> MRV Newsletter October 2023 (Updated: 1 November 2023, Please download again)
Read More European Medicines Agency recommends Opdivo for treatment of earlier melanoma stages
Opdivo (nivolumab) is a programmed cell death protein 1 (PD-1) inhibitor.